Adenovirus-vectored Ebola vaccines

References

• Feldmann H, Slenczka W, Klenk HD. Emerging and reemerging of filoviruses. Arch Virol 1996;11:77-100.
   Google Scholar
• Feldmann H, Klenk HD. Filoviruses. In: Baron S, Editor. Medical microbiology. The University of Texas Medical Branch at Galveston, Galveston TX, 1996
   Google Scholar
• Le Guenno B, Formenty P, Wyers M, et al. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995;345(8960):1271-4
   PubMed Web of Science ®Google Scholar
• Towner JS, Sealy TK, Khristova ML, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008;4(11):e1000212
   PubMed Web of Science ®Google Scholar
• Rouquet P, Froment JM, Bermejo M, et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 2005;11(2):283-90
   PubMed Web of Science ®Google Scholar
• Rewar S, Mirdha D. Transmission of Ebola virus disease: An overview. Annals of global health 2014;80(6):444-51
   PubMed Web of Science ®Google Scholar
• WHO. Ebola situation report - 27 May 2015. http://apps.who.int/ebola/current-situation/ebola-situation-report-27-may-2015
   Google Scholar
• Mackay IM, Arden KE. Ebola virus in the semen of convalescent men. Lancet Infect Dis 2015;15(2):149-50
   PubMed Web of Science ®Google Scholar
• Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 2015;372(25):2423-7
   Google Scholar
• Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther 2009;17(8):1333-9
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-93
   PubMed Web of Science ®Google Scholar
• Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010;5(5):357-61
   PubMed Web of Science ®Google Scholar
• Stephenson KE, Hural J, Buchbinder SP, et al. Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J Infect Dis 2012;205(12):1806-10
   PubMed Web of Science ®Google Scholar
• Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009;106(47):19940-5
   PubMed Web of Science ®Google Scholar
• Hutnick NA, Carnathan DG, Dubey SA, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 2009;15(8):876-8
   PubMed Web of Science ®Google Scholar
• Gentile G, Venditti M, Micozzi A, et al. Cryptosporidiosis in patients with hematologic malignancies. Rev Infect Dis 1991;13(5):842-6
   PubMedGoogle Scholar
• Masek-Hammerman K, Li H, Liu J, et al. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol 2010;84(19):9810-16
   PubMed Web of Science ®Google Scholar
• Cheng C, Wang L, Gall JG, et al. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS One 2012;7(4):e33969
   PubMed Web of Science ®Google Scholar
• Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008;205(12):2717-25
   PubMed Web of Science ®Google Scholar
• Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005;174(11):7179-85
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006;346(2):394-401
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011;85(9):4222-33
   PubMed Web of Science ®Google Scholar
• Alcock R, Cottingham MG, Rollier CS, et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2010;2(19):19ra12
   PubMed Web of Science ®Google Scholar
• Schooley RT, Spritzler J, Wang H, et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010;202(5):705-16
   PubMed Web of Science ®Google Scholar
• O’Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012;205(5):772-81
   PubMed Web of Science ®Google Scholar
• Kimani D, Jagne YJ, Cox M, et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol Ther 2014;22(11):1992-2003
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther 2014;22(3):668-74
   PubMed Web of Science ®Google Scholar
• Lubaroff DM, Konety BR, Link B, et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009;15(23):7375-80
   PubMed Web of Science ®Google Scholar
• Vellinga J, Smith JP, Lipiec A, et al. Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum Gene Ther 2014;25(4):318-27
   PubMed Web of Science ®Google Scholar
• Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med 1998;4(1):37-42
   PubMed Web of Science ®Google Scholar
• Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998;246(1):134-44
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408(6812):605-9
   PubMed Web of Science ®Google Scholar
• Hanke T, Blanchard TJ, Schneider J, et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16(5):439-45
   PubMed Web of Science ®Google Scholar
• Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4(4):397-402
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424(6949):681-4
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006;3(6):e177
   PubMed Web of Science ®Google Scholar
• Dudareva M, Andrews L, Gilbert SC, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009;27(27):3501-4
   PubMed Web of Science ®Google Scholar
• Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012;4(115):115ra112
   Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014;20(10):1126-9
   PubMed Web of Science ®Google Scholar
• Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014;6(261):261ra153
   PubMed Web of Science ®Google Scholar
• Capone S, Reyes-Sandoval A, Naddeo M, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010;29(2):256-65
   PubMed Web of Science ®Google Scholar
• Wang D, Raja NU, Trubey CM, et al. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J Virol 2006;80(6):2738-46
   PubMed Web of Science ®Google Scholar
• Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010;17(4):572-81
   PubMed Web of Science ®Google Scholar
• Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009;4(4):e5308
   PubMed Web of Science ®Google Scholar
• Richardson JS, Wong G, Pillet S, et al. Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. J Bioterror Biodef 2011;(Suppl 1):pii: 007
   Google Scholar
• Wong G, Richardson JS, Pillet S, et al. adenovirus-vectored vaccine provides postexposure protection to Ebola virus-infected nonhuman primates. J Infect Dis 2015. [Epub ahead of print]
   Google Scholar
• Haas CN. On the quarantine period for ebola virus. PLoS currents 2014;6
   Google Scholar
• Wong G, Richardson JS, Cutts T, et al. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Antiviral Res 2015;116:17-19
   PubMed Web of Science ®Google Scholar
• Choi JH, Jonsson-Schmunk K, Qiu X, et al. A single dose respiratory recombinant adenovirus-based vaccine provides long-term protection for non-human primates from lethal Ebola infection. Mol Pharm 2014. [Epub ahead of print]
   Google Scholar
• RSV001 - A new vaccine to prevent severe viral chest infections. Available from: https://clinicaltrials.gov/ct2/show/NCT01805921
   Google Scholar
• Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol 2003;77(18):9733-7
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006;13(11):1267-77
   PubMed Web of Science ®Google Scholar
• Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000;19(7-8):764-78
   PubMed Web of Science ®Google Scholar
• Moorthy VS, McConkey S, Roberts M, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003;21(17-18):2004-11
   Web of Science ®Google Scholar
• Moorthy VS, Imoukhuede EB, Keating S, et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004;189(12):2213-19
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998;9(13):1909-17
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010;29(2):304-13
   PubMed Web of Science ®Google Scholar
• Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 2015;211(4):549-57
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015;385:2272-9
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4(115):115ra111
   Web of Science ®Google Scholar
• Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine - preliminary report. N Engl J Med 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Rampling T, Ewer K, Bowyer G, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report. N Engl J Med 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009;7(5):393-400
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011;17(9):1128-31
   PubMed Web of Science ®Google Scholar
• Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine - preliminary report. N Engl J Med 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Preliminary Report. N Engl J Med 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Shuchman M. Ebola vaccine trial in west Africa faces criticism. Lancet 2015;385:1933-4
   PubMed Web of Science ®Google Scholar
• Phase 1 Trial of Ebola Vaccine in Mali. Available from: https://clinicaltrials.gov/ct2/show/NCT02267109
   Google Scholar
• A clinical trial on the candidate vaccine cAd3-EBOZ in healthy adults in Switzerland. Available from: https://clinicaltrials.gov/ct2/show/NCT02289027
   Google Scholar
• A Safety and immunogenicity study of heterologous prime-boost ebola vaccine regimens in healthy participants. Available from: https://clinicaltrials.gov/ct2/show/NCT02313077
   Google Scholar
• Clinical trial of the cAd3-EBO and cAd3-EBOZ Ebola vaccines in healthy adults in uganda. Available from: https://clinicaltrials.gov/ct2/show/NCT02354404
   Google Scholar
• Partnership for research on ebola vaccines in liberia (PREVAIL). Available from: https://clinicaltrials.gov/ct2/show/NCT02344407
   Google Scholar
• A study to evaluate the safety and immunogenicity of heterologous prime-boost ebola vaccine regimens in healthy participants. Available from: www.clinicaltrials.gov/ct2/show/NCT02376426
   Google Scholar
• A Safety and immunogenicity study of heterologous and homologous prime-boost ebola vaccine regimens in healthy participants. Available from: https://clinicaltrials.gov/ct2/show/NCT02325050
   Google Scholar